Welcome to our dedicated page for Cryoport SEC filings (Ticker: CYRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cryoport, Inc. filings document the regulatory record for a Nasdaq-listed Nevada corporation providing temperature-controlled supply chain solutions to life sciences customers. Recent Form 8-K reports furnish quarterly and annual results releases, while definitive proxy materials describe governance matters, stockholder voting items and business updates tied to Life Sciences Services and Life Sciences Products.
The filing record also identifies Cryoport's registered common stock and recurring disclosure subjects such as operating performance, commercial and clinical cell and gene therapy support, biostorage and bioservices activity, cryogenic systems demand, executive and board governance, and stockholder meeting materials.
Robert Stefanovich, Chief Financial Officer of Cryoport, Inc. (CYRX), reported option exercises and a sale on 08/19/2025. He exercised 26,164 stock options with an exercise price of $3.07, producing 26,164 shares. To cover the exercise cost, he sold 9,300 shares in multiple transactions at a weighted-average price of $8.6686 (individual sale prices ranged from $8.60 to $8.75). After these transactions he beneficially owned 207,213 shares. The option grant vests 1/48 each month beginning August 19, 2015.
CryoPort, Inc. (CYRX) Form 144 notice: The filing reports a proposed sale of 9,300 common shares, with an aggregate market value of $80,617.98, from a total of 50,066,968 shares outstanding. The shares are to be sold on 08/19/2025 on NASDAQ through Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY. The filing states the shares were acquired on 08/19/2025 by exercise of options under a registered plan and were paid for in cash. The filer reports no securities sold in the past three months and affirms no undisclosed material adverse information.
CryoPort insider exercise and share ownership update. Jerrell Shelton, President and CEO and a director of CryoPort, exercised options on 08/13/2025 to acquire 25,000 shares of common stock at an exercise price of $5. After this cash exercise, Shelton beneficially owns 1,062,419 shares. The option grant referenced vests monthly over 48 months beginning 08/19/2015; the exercised options were part of that schedule. The filing indicates the exercise was a cash exercise and there was no immediate sale of the underlying shares.
Alger Associates, Inc. filed an amendment to Schedule 13G reporting beneficial ownership of 2,358,940 shares of CryoPort, Inc. common stock, representing 4.7% of the outstanding class. The filing states Alger Associates has sole voting and sole dispositive power over these shares and that the securities are held in the ordinary course of business, not for the purpose of changing or influencing control. The filing identifies Fred Alger Management, LLC and Alger Group Holdings as related entities that manage accounts holding the securities.
Brown Capital Management, LLC filed an amended Schedule 13G reporting beneficial ownership of 3,798,962 shares of CryoPort Inc. common stock, representing 7.58% of the class. The filing states Brown Capital has sole voting power over 1,529,549 shares and sole dispositive power over all 3,798,962 shares. The shares are held by various investment advisory clients of Brown Capital, which the firm says gives it beneficial ownership under Rule 13d-3 because of its discretionary authority to direct investment and voting decisions. The filing includes a certification that the holdings are held in the ordinary course of business and are not intended to influence control of the issuer.
Cryoport completed the divestiture of its CryoPDP specialty courier business to DHL for $133.0 million, which included repayment of approximately $77.2 million of intercompany loans and generated a reported $116,662 thousand gain on disposal classified as discontinued operations. Proceeds from the divested business of $210,239 thousand were reflected in investing cash flows and materially increased the Company's liquidity.
Total revenue increased to $45,454 thousand for the three months ended June 30, 2025 (up from $39,709) and to $86,494 thousand for the six months (up from $77,000). Results from continuing operations remained a loss: $(12,014) thousand for the quarter and $(18,752) thousand for the six months, while net income including discontinued operations was $105,180 thousand and $93,199 thousand, respectively. Cash and cash equivalents rose to $243,416 thousand at June 30, 2025; total assets were $773,927 thousand and total stockholders' equity was $515,391 thousand. Convertible senior notes noncurrent balance was $184,504 thousand and accumulated impairment losses related to goodwill/intangibles totaled $104,132 thousand.
On 08/04/2025 Cryoport (CYRX) filed a Form 4 showing that President & CEO Jerrell Shelton exercised 25,000 stock options at an exercise price of $5 on 07/31/2025. This was a cash exercise with no subsequent sale of the underlying shares. As a result, Shelton’s direct holdings rose to 1,037,419 common shares.
The option was originally granted on 08/20/2015 and vested in equal monthly installments over 48 months; the filing confirms the award is now fully exercised and retired. The transaction modestly increases insider ownership and may indicate management confidence, but represents only about 2.4 % of Shelton’s total stake and does not involve open-market buying. No additional financial metrics, earnings data, or strategic commentary were included in the filing.